<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease - Geake, JB - 2015 | Cochrane Library</title> <meta content="Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease - Geake, JB - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010139.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease - Geake, JB - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010139.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010139.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Indacaterol, a once‐daily beta&lt;sub&gt;2&lt;/sub&gt;‐agonist, versus twice‐daily beta&lt;sub&gt;2&lt;/sub&gt;‐agonists or placebo for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="James B Geake" name="citation_author"/> <meta content="The Prince Charles Hospital" name="citation_author_institution"/> <meta content="jamesgeake@gmail.com" name="citation_author_email"/> <meta content="Eli J Dabscheck" name="citation_author"/> <meta content="Alfred Hospital" name="citation_author_institution"/> <meta content="Richard Wood‐Baker" name="citation_author"/> <meta content="University of Tasmania" name="citation_author_institution"/> <meta content="Christopher J Cates" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010139.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010139.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010139.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010139.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐2 Receptor Agonists [*administration &amp; dosage]; Drug Administration Schedule; Forced Expiratory Volume [physiology]; Formoterol Fumarate [administration &amp; dosage]; Indans [*administration &amp; dosage]; Pulmonary Disease, Chronic Obstructive [drug therapy]; Quinolones [*administration &amp; dosage]; Randomized Controlled Trials as Topic; Salmeterol Xinafoate [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010139.pub2&amp;doi=10.1002/14651858.CD010139.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010139\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010139\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010139.pub2",title:"Indacaterol, a once\\u2010daily beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonist, versus twice\\u2010daily beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonists or placebo for chronic obstructive pulmonary disease",firstPublishedDate:"Jan 10, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010139.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010139.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010139.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010139.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010139.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010139.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010139.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010139.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010139.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010139.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1737 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010139.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/appendices#CD010139-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/table_n/CD010139StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/table_n/CD010139StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Indacaterol, a once‐daily beta<sub>2</sub>‐agonist, versus twice‐daily beta<sub>2</sub>‐agonists or placebo for chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#CD010139-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>James B Geake</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#CD010139-cr-0003">Eli J Dabscheck</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#CD010139-cr-0004">Richard Wood‐Baker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information#CD010139-cr-0005">Christopher J Cates</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information/en#CD010139-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010139.pub2">https://doi.org/10.1002/14651858.CD010139.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010139-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010139-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010139-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010139-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010139-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010139-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010139-abs-0001" lang="en"> <section id="CD010139-sec-0001"> <h3 class="title" id="CD010139-sec-0001">Background</h3> <p>Indacaterol is an inhaled long‐acting beta<sub>2</sub>‐agonist that is administered once daily and has been investigated as a treatment for chronic obstructive pulmonary disease (COPD). Four different doses have been investigated (75 mcg, 150 mcg, 300 mcg and 600 mcg). The relative effects of different doses of once‐daily indacaterol in the management of patients with COPD are uncertain. </p> </section> <section id="CD010139-sec-0002"> <h3 class="title" id="CD010139-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of indacaterol versus placebo and alternative twice‐daily long‐acting beta<sub>2</sub>‐agonists for the treatment of patients with stable COPD. </p> </section> <section id="CD010139-sec-0003"> <h3 class="title" id="CD010139-sec-0003">Search methods</h3> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), handsearched respiratory journals and meeting abstracts and searched the Novartis trials registry and ClinicalTrials.gov. The date of the most recent search was 8 November 2014. </p> </section> <section id="CD010139-sec-0004"> <h3 class="title" id="CD010139-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials comparing indacaterol at any dose versus placebo or alternative long‐acting beta<sub>2</sub>‐agonists. Trials were required to be of at least 12 weeks' duration and had to include adults older than 18 years with a confirmed spirometric diagnosis of COPD. </p> </section> <section id="CD010139-sec-0005"> <h3 class="title" id="CD010139-sec-0005">Data collection and analysis</h3> <p>Two review authors (JBG, EJD) independently assessed for possible inclusion all citations identified as a result of the search. Disagreements were resolved through discussion or, if required, through resolution by a third review author (RWB). One review author (JBG) extracted data from trials identified by the search and entered these data into Review Manager 5.1 for statistical analysis. Data entry was cross‐checked by a second review author (EJD, CJC). </p> </section> <section id="CD010139-sec-0006"> <h3 class="title" id="CD010139-sec-0006">Main results</h3> <p>A total of 13 trials with 9961 participants were included in the review. Ten trials with a total of 8562 participants involved an indacaterol versus placebo comparison. Five trials with a total of 4133 participants involved an indacaterol versus twice‐daily beta<sub>2</sub>‐agonist comparison. The comparator beta<sub>2</sub>‐agonists were salmeterol, formoterol and eformoterol. One of these trials, with a total of 90 participants, provided no data that could be used in this review. Two trials included both indacaterol versus placebo and indacaterol versus twice‐daily beta<sub>2</sub>‐agonist comparisons. Trials were between 12 weeks and 52 weeks in duration. Overall the quality of the evidence was strong, and risk of significant bias was minimal in most of the included studies. Enrolled participants had stable COPD across a range of spirometric severities. Forced expiratory volume in 1 second (FEV<sub>1</sub>) was generally between 30% and 80% predicted, and a mean FEV<sub>1</sub> of approximately 50% was predicted in most studies. Patients with concurrent respiratory disease, including asthma, were excluded. Concomitant use of inhaled corticosteroids was permitted. </p> <p>The primary objectives were to compare trough FEV<sub>1</sub> at the end of dosing, exacerbation rates and quality of life. Significant adverse events, mortality and dyspnoea were included as secondary outcomes. Compared with placebo, a significant and clinically relevant improvement in trough FEV<sub>1</sub> was noted with indacaterol (mean difference (MD) 149.11, 95% confidence interval (CI) 137.09 to 161.12). In addition, compared with placebo, a significant improvement in mean St George Respiratory Questionaire (SGRQ) score (MD ‐3.60, 95% CI ‐4.36 to ‐2.83) was reported, and the proportion of participants experiencing clinically relevant improvement in SGRQ score was significantly greater (odds ratio (OR) 1.64, 95% CI 1.46 to 1.845. Compared with twice‐daily beta<sub>2</sub>‐agonists, a small but statistically significant increase in trough FEV<sub>1</sub> was seen with indacaterol (MD 61.71 mL, 95% CI 41.24 to 82.17). Differences between indacaterol and twice‐daily beta<sub>2</sub>‐agonists in mean SGRQ scores (MD ‐0.81, 95% CI ‐2.28 to 0.66) and in the proportions of participants achieving clinically relevant improvements in SGRQ scores (OR 1.07, 95% CI 0.87 to 1.32) were not statistically significant, but the confidence intervals are too wide to permit the conclusion that the treatments were equivalent. </p> </section> <section id="CD010139-sec-0007"> <h3 class="title" id="CD010139-sec-0007">Authors' conclusions</h3> <p>For patients with stable COPD, use of indacaterol versus placebo results in statistically significant and clinically meaningful improvements in lung function and quality of life. The clinical benefit for lung function is at least as good as that seen with twice‐daily long‐acting beta<sub>2</sub>‐agonists, but the comparative effect on quality of life remains uncertain, as important differences cannot be excluded. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010139-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010139-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010139-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010139-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010139-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010139-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010139-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010139-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010139-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010139-abs-0003" lang="en"> <h3>Indacaterol for the treatment of people with stable COPD</h3> <p><b>Review question</b> </p> <p>1. What is the effect of treatment with indacaterol versus no treatment on stable COPD? </p> <p>2. What is the effect of treatment with indacaterol versus twice‐daily beta<sub>2</sub>‐agonists on stable COPD? </p> <p><b>Background</b> </p> <p>Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that causes shortness of breath and impairs quality of life. In addition, sudden worsening of symptoms (acute exacerbations) may require additional treatment or hospitalisation and may result in further impairment in quality of life. </p> <p>Several different medicines can be used to treat patients with COPD; inhaled long‐acting beta<sub>2</sub>‐agonists are one example. Until recently, inhaled long‐acting beta<sub>2</sub>‐agonists required twice‐daily dosing. Indacaterol is an inhaled beta<sub>2</sub>‐agonist that requires once‐daily dosing. </p> <p>We aimed to assess the following.</p> <p>1. The effect of indacaterol in the treatment of participants with stable COPD.</p> <p>2. How indacaterol compares with available alternative twice‐daily long‐acting beta<sub>2</sub>‐agonists. </p> <p><b>Study characteristics</b> </p> <p>13 trials with a total of 9961 participants were included in this review. Ten trials with a total of 8562 participants involved an indacaterol versus placebo comparison. Five trials with a total of 4133 participants involved an indacaterol versus twice‐daily beta<sub>2</sub>‐agonist comparison. Two trials included both indacaterol versus placebo and indacaterol versus twice‐daily beta<sub>2</sub>‐agonist comparisons. Trials were between 12 and 52 weeks duration and compared doses between 75 mcg and 600 mcg. In most trials, mean forced expiratory volume in 1 second (FEV<sub>1</sub>) was approximately 50% predicted. </p> <p><b>Key results</b> </p> <p>1. Indacaterol is an effective medication for the treatment of patients with stable COPD. It results in improved lung function and quality of life. </p> <p>2. Indacaterol led to improvements in lung function that were clinically similar to those seen with twice‐daily long‐acting beta<sub>2</sub>‐agonists. </p> <p>3. No measurable difference was noted between indacaterol and twice‐daily long‐acting beta<sub>2</sub>‐agonists with respect to quality of life, but important differences cannot be excluded. </p> <p>4. No significant difference was observed in the number of participants suffering a serious adverse event or mortality, but the confidence intervals were too wide because very few events could be used to rule out important differences. </p> <p><b>Quality of the evidence</b> </p> <p>Overall the quality of the evidence was judged to be high.</p> <p><b>Summary</b> </p> <p>Indacaterol is an effective treatment for patients with stable COPD; it offers benefits that are clinically similar to those of existing twice‐daily preparations within the same class of medication but provides the possible advantage of once‐daily dosing. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010139-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010139-sec-0100"></div> <h3 class="title" id="CD010139-sec-0101">Implications for practice</h3> <section id="CD010139-sec-0101"> <p>Indacaterol provides clinically meaningful improvements in lung function that are associated with improvements in quality of life and dyspnoea across all doses between 75 mcg and 600 mcg. In addition, indacaterol reduces the chance of experiencing an exacerbation. Indacaterol is therefore an appropriate treatment for patients with confirmed symptomatic stable COPD who do not have concurrent respiratory disease including asthma. </p> <p>Indacaterol offers an alternative to twice‐daily beta<sub>2</sub>‐agonists and results in clinically similar improvements in lung function, with the possible advantage of once‐daily dosing. Some uncertainty remains regarding its effect on quality of life, however the effects of indacaterol and twice‐daily beta<sub>2</sub>‐agonists for this outcome are likely comparable. </p> <p>Evidence is currently insufficient to confirm the effects of indacaterol on serious adverse events and mortality. </p> </section> <h3 class="title" id="CD010139-sec-0102">Implications for research</h3> <section id="CD010139-sec-0102"> <p> <ol id="CD010139-list-0008"> <li> <p>Further long‐term data would be useful for defining the impact of indacaterol on exacerbations, serious adverse events and mortality. </p> </li> <li> <p>Further data would be useful for defining potential differences in efficacy between indacaterol and alternative long‐acting beta<sub>2</sub>‐agonists, particularly with respect to quality of life and dyspnoea. </p> </li> <li> <p>Further data examining potential dose‐response curves would be useful, particularly with respect to severity of underlying COPD. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010139-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010139-sec-0029"></div> <div class="table" id="CD010139-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Indacaterol versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Indacaterol versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> indacaterol </p> <p><b>Comparator:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Indacaterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐study trough FEV<sub>1</sub> </b> <br/> mL<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in control groups was<br/> <b>1170 to 1360 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in the intervention groups was<br/> <b>149.11 mL higher</b> <br/> (137.09 to 161.12 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5001<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This value is greater than the minimum clinically important difference of 100 mL (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with a clinically significant improvement in QOL</b> <br/> SGRQ<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>548 per 1000</b> <br/> (519 to 578)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.64</b> <br/> (1.46 to 1.845 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4906<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with clinically significant improvement in dyspnoea</b> <br/> TDI<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> <br/> (576 to 636)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.96</b> <br/> (1.73 to 2.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4577<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing 1 or more exacerbations</b> <br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> <br/> (167 to 212) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b> <br/> (0.7 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4807<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (60 to 87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b> <br/> (0.82 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6065<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (1 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.42</b> <br/> (0.16 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5694<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk calculated from raw responder numbers in placebo arm at end of treatment. Absolute benefit and 95% CIs calculated from <a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>.<br/> <sup>b</sup>95% CIs around the point estimate of effect include both appreciable benefit and no difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010139-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Indacaterol versus twice‐daily long‐acting beta2‐agonists for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Indacaterol versus twice‐daily long‐acting beta<sub>2</sub>‐agonists for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> indacaterol<br/> <b>Comparison:</b> twice‐daily long‐acting beta<sub>2</sub>‐agonists </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Twice‐daily long‐acting beta<sub>2</sub>‐agonists</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Indacaterol </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐study trough FEV<sub>1</sub> </b> <br/> mL<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in the control groups was <b>1310 to 1390 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in the intervention groups was<br/> <b>73.76 mL higher</b> <br/> (57.33 to 90.19 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2708<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This value is less than the minimum clinically important difference of 100 mL<sup>d</sup> (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with a clinically significant improvement in quality of life</b> <br/> SGRQ<br/> Follow‐up: 26 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>498 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>515 per 1000</b> <br/> (464 to 567)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.07</b> <br/> (0.87 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1520<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with a clinically significant improvement in dyspnoea</b> <br/> TDI<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b> <br/> (566 to 647)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b> <br/> (0.94 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2536<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing at least 1 exacerbation</b> <br/> Exacerbations<br/> Follow‐up: 26 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> <br/> (215 to 297) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.07</b> <br/> (0.86 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1869<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Adverse events<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> <br/> (63 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.02</b> <br/> (0.79 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3266<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Deaths<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (1 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b> <br/> (0.31 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3266<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk taken from raw responder numbers at the end of treatment. Absolute risk and 95% CIs calculated from <a href="http://www.nntonline.net/visualrx" target="_blank">www.nntonline.net/visualrx</a>.<br/> <sup>b</sup>95% CIs around the point estimate of effect include both no difference and appreciable benefit.<br/> <sup>c</sup>95% CIs around the point estimate of effect include both significant benefit and significant harm. </p> <p><sup>d</sup>Minimum clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010139-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010139-sec-0030"></div> <p>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Several pharmacotherapeutic interventions have demonstrated efficacy in modifying a variety of long‐term clinical outcomes associated with the disease. These include inhaled corticosteroids, inhaled long‐acting muscarinic antagonists and inhaled long‐acting beta<sub>2</sub>‐agonists. The latter class, used alone or in combination, has an established role in the treatment of COPD, particularly with respect to reducing exacerbations and improving quality of life. Until recently, although these agents have been classed as 'long‐acting,' their pharmacokinetic profile has required twice‐daily dosing. Indacaterol is a new beta<sub>2</sub>‐agonist that is administered once daily and has recently been approved by several regulatory authorities around the world for the treatment of patients with stable COPD. As it requires only once‐daily dosing, indacaterol offers possible benefits for adherence over previously available agents. </p> <section id="CD010139-sec-0031"> <h3 class="title" id="CD010139-sec-0031">Description of the condition</h3> <p>Chronic obstructive pulmonary disease was the fifth leading cause of death worldwide in 2002, and is projected to become the third leading cause by 2030 (<a href="./references#CD010139-bbs2-0042" title="World Health Organization. World Health Statistics. www.who.int/whosis/whostat/2008/en/index.html(accessed 3 September 2012). ">WHO 2008</a>). It presents a considerable financial and social burden for both societies and individuals (<a href="./references#CD010139-bbs2-0028" title="BuistAS , McBurnieMA , VollmerWM , GillespieS , BurneyP , ManninoDM , et al. International variation in the prevalence of COPD (the BOLD Study): a population‐based prevalence study. Lancet2007;370(9589):741‐50. [PUBMED: 17765523] ">Buist 2007</a>; <a href="./references#CD010139-bbs2-0032" title="GershonAS , WangC , WiltonAS , RautR , ToT . Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population‐based study. Archives of Internal Medicine2010;170(6):560‐5. [PUBMED: 20308643] ">Gershon 2010</a>). This chronic, usually progressive disease, which is characterised by airflow limitation that is not fully reversible, occurs as a consequence of exposure to noxious particles or gases (<a href="./references#CD010139-bbs2-0033" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf (accessed 12 March 2014). ">GOLD 2014</a>). Exposure to cigarette smoke is the most important risk factor for development of the disease in high‐income countries. In low‐income countries, exposure to smoke from the burning of biomass fuels indoors has been identified as an additional important cause. Although patients may be asymptomatic in early stages of disease, its clinical course is characterised by progressive dyspnoea, often associated with chronic cough and sputum production. This course is often punctuated by 'exacerbations,' defined as acute deterioration in symptoms of dyspnoea, cough or sputum beyond day‐to‐day fluctuations in the disease. Such exacerbations have a major impact on quality of life and in developed countries account for the greatest burden on healthcare systems (<a href="./references#CD010139-bbs2-0033" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf (accessed 12 March 2014). ">GOLD 2014</a>). </p> </section> <section id="CD010139-sec-0032"> <h3 class="title" id="CD010139-sec-0032">Description of the intervention</h3> <p>Indacaterol is an inhaled once‐daily beta<sub>2</sub>‐agonist that results in smooth muscle relaxation and bronchodilation. It has been investigated for the treatment of patients with COPD, predominantly those with moderate to severe spirometric deficits. It was approved in 2009 by the European Medicines Agency (EMA) for the treatment of patients with COPD and in 2011 by the Food and Drug Administration (FDA) in the United States. </p> </section> <section id="CD010139-sec-0033"> <h3 class="title" id="CD010139-sec-0033">How the intervention might work</h3> <p>Similar to other beta<sub>2</sub>‐agonists, indacaterol is thought to work through stimulation of beta<sub>2</sub>‐adrenergic receptors within respiratory smooth muscle, resulting in bronchodilation. This in turn improves respiratory mechanics, resulting in improved dyspnoea. </p> </section> <section id="CD010139-sec-0034"> <h3 class="title" id="CD010139-sec-0034">Why it is important to do this review</h3> <p>Chronic obstructive pulmonary disease is a common disorder that is associated with significant morbidity and mortality. Given the irreversible effects of the disease, available pharmacological options for its treatment are relatively limited. As it was recently approved across several healthcare jurisdictions, including Europe and the United States, prescription of this medication is likely to escalate in the future. Therefore it is important that potential prescribers have a keen understanding of the efficacy and safety of this drug, both in its own right and compared with other available treatments for the disease, in particular, twice‐daily long‐acting beta<sub>2</sub>‐agonists. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010139-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010139-sec-0035"></div> <p>To compare the efficacy and safety of indacaterol versus placebo and alternative twice‐daily long‐acting beta<sub>2</sub>‐agonists for the treatment of patients with stable COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010139-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010139-sec-0036"></div> <section id="CD010139-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010139-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials of at least 12 weeks' duration. We did not exclude trials on the basis of blinding. Trials using additional bronchodilators that were not part of the comparison were excluded because of the possibility that they might introduce bias. </p> </section> <section id="CD010139-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults older than 18 years with a confirmed spirometric diagnosis of COPD.</p> </section> <section id="CD010139-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD010139-list-0001"> <li> <p>Experimental intervention: once‐daily indacaterol at any dose.</p> </li> <li> <p>Comparator interventions:</p> <ol id="CD010139-list-0002"> <li> <p>Placebo.</p> </li> <li> <p>Twice‐daily long‐acting beta<sub>2</sub>‐agonists. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD010139-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>Outcome measures did not form part of the eligibility criteria for inclusion of studies in this review. </p> <section id="CD010139-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010139-list-0003"> <li> <p>Trough forced expiratory volume in one second (FEV<sub>1</sub>). </p> </li> <li> <p>Mean difference in quality of life.</p> </li> <li> <p>Number of participants with a clinically significant improvement in quality of life.</p> </li> </ol> </p> </section> <section id="CD010139-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010139-list-0004"> <li> <p>Peak FEV<sub>1</sub>. </p> </li> <li> <p>Mean difference in dyspnoea.</p> </li> <li> <p>Number of participants experiencing a clinically significant improvement in dyspnoea.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Mortality.</p> </li> <li> <p>Number of participants experiencing at least one protocol‐defined exacerbation.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010139-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010139-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is maintained by the Information Specialist for the group. The register is derived from systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD010139-sec-0106">Appendix 1</a> for further details). The TSC searched all records in the CAGR coded as 'COPD' using the following terms: </p> <p>(indacaterol or OnBrez or Breezhaler or Arcapta or ultra‐long* or "ultra long*").</p> <p>This search was carried out in August 2014. We also conducted a search of ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and of the Novartis clinical trials registry (<a href="http://www.novctrd.com" target="_blank">www.novctrd.com</a>). We searched all databases from their inception to the present and imposed no restriction on language of publication. </p> </section> <section id="CD010139-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and asked them to identify other published and unpublished studies. We also contacted manufacturers and experts in the field. </p> </section> </section> <section id="CD010139-sec-0047"> <h3 class="title" id="CD010139-sec-0047">Data collection and analysis</h3> <section id="CD010139-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JBG, EJD) independently assessed for potential inclusion all citations that were identified as a result of the search. Disagreement was resolved through discussion. Abstracts and full‐text papers were assessed for inclusion, and disagreements were resolved through discussion or, if required, through resolution by a third review author (RWB). </p> </section> <section id="CD010139-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>One review author (JBG) extracted data from trials identified by the search and entered these data into Review Manager 5.1 (<a href="./references#CD010139-bbs2-0039" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>) for statistical analysis. Data were cross‐checked by a second review author (EJD, CJC). </p> </section> <section id="CD010139-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JBG, EJD) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010139-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). Disagreements were resolved by discussion and through consultation with a third review author (RWB). We assessed risk of bias according to the following domains. </p> <p> <ol id="CD010139-list-0005"> <li> <p>Allocation sequence generation.</p> </li> <li> <p>Concealment of allocation.</p> </li> <li> <p>Blinding of participants and investigators.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> </ol> </p> <p>Each source of bias was graded as having low, high or unclear risk.</p> </section> <section id="CD010139-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs) using the Mantel‐Haenszel method. We analysed continuous data using mean differences (MDs). </p> </section> <section id="CD010139-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Dichotomous data were analysed using participants rather than events as the unit of analysis. For repeated observations, the longest follow‐up from each study was selected. When an estimate of an effect measure was presented (rather than summary data for the intervention group) and a P value or a confidence interval (CI) was provided, the standard error (SE) was estimated as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010139-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010139-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>Investigators and study sponsors were contacted to verify key study characteristics and to provide missing numerical outcome data when possible. Data were analysed on an intention‐to‐treat basis, except in some instances where the study sponsor was required to provide outcome data where there were small numerical differences between the participants randomised and participants analysed. </p> </section> <section id="CD010139-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity among the trials included in each analysis. We considered I<sup>2</sup> &gt; 50% to be significant (see protocol), and when this was the case, potential causes of heterogeneity were explored. We postulated a priori that potential sources of heterogeneity would be due to the following. </p> <p> <ol id="CD010139-list-0006"> <li> <p>Differences in methodological quality and risk of bias.</p> </li> <li> <p>Differences in usage of concomitant inhaled and systemic medications.</p> </li> <li> <p>Differences in doses of indacaterol or comparator long‐acting beta<sub>2</sub>‐agonists. </p> </li> </ol> </p> </section> <section id="CD010139-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We contacted study authors and manufacturers to obtain missing outcome data. We identified additional trials by searching the manufacturers' trial registers, by contacting the manufacturers directly and by searching ClinicalTrials.gov (http://clinicaltrials.gov/).   </p> </section> <section id="CD010139-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used adjusted analysis of covariance (ANCOVA) as the primary method of synthesising study results when these were available, and we combined them using the generic inverse variance method in RevMan. This method was not specified in the protocol but offers the advantage of taking into account participant characteristics (including baseline values). When such data were not available, we used raw end‐of‐study data instead. Types of outcome data used for FEV<sub>1</sub>, quality of life and dyspnoea are included in <a href="#CD010139-tbl-0003">Table 1</a> and <a href="#CD010139-tbl-0004">Table 2</a>. </p> <div class="table" id="CD010139-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data extraction for indacaterol versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> FEV<sub>1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean SGRQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> SGRQ responders</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI responders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0004" title="FeldmanG , SilerT , PrasadN , JackD , PiggottS , OwenR , et al. Efficacy and safety of indacaterol 150mcg once‐daily in COPD: a double‐blind randomised 12‐week study. BMC Pulmonary Medicine2010;10:11. ">Feldman 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0001" title="BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal 2013 May 30 [Epub ahead of print]. [DOI: 10.1183/09031936.00200212] ">Bateman 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Raw data used for analysis by trial duration (12‐week data). </p> </div> </div> <div class="table" id="CD010139-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data extraction for indacaterol versus alternative twice‐daily long‐acting beta2‐agonists</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> FEV<sub>1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean SGRQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> SGRQ responders</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI responders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>12‐Week raw data. </p> </div> </div> <p>A 'Summary of findings' table for six key outcomes in each comparison was created using GRADEpro software, in keeping with methods described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010139-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). Additional results are detailed in the body of this report. </p> </section> <section id="CD010139-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD010139-list-0007"> <li> <p>Global Initiative on Obstructive Lung Disease (GOLD) class 2, GOLD class 3 and GOLD class 4 for both placebo and long‐acting beta<sub>2</sub>‐agonist (LABA) comparisons. </p> </li> <li> <p>Salmeterol versus formoterol/eformoterol for LABA comparison.</p> </li> <li> <p>Trials of between 12 and 24 weeks and trials ≥ 24 weeks.</p> </li> </ol> </p> <p>We used only primary outcomes for these subgroup analyses. We performed subgroup analyses according to indacaterol dose on both primary and secondary outcomes as post hoc analyses. </p> <p>When we identified substantial heterogeneity, we explored this by performing a sensitivity analysis; we systematically excluded studies from the overall analysis on the basis of potential sources of heterogeneity as mentioned above. </p> </section> <section id="CD010139-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We investigated studies at high risk of bias by removing these studies as part of a sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010139-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010139-sec-0059"></div> <section id="CD010139-sec-0060"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010139-sec-0133" title="">Characteristics of included studies</a> and <a href="./references#CD010139-sec-0134" title="">Characteristics of excluded studies</a>. </p> <section id="CD010139-sec-0061"> <h4 class="title">Results of the search</h4> <p>The search retrieved 194 references. A total of 117 records were screened after duplicates were removed. Twelve were ultimately included for quantitative analysis (<a href="#CD010139-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010139-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010139-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010139-sec-0062"> <h4 class="title">Included studies</h4> <p>A total of 13 trials were identified for inclusion. Two trials compared indacaterol versus both placebo and an alternative long‐acting beta<sub>2</sub>‐agonist.(<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>). Ten trials with a total of 8562 participants involved a placebo comparison (<a href="./references#CD010139-bbs2-0001" title="BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal 2013 May 30 [Epub ahead of print]. [DOI: 10.1183/09031936.00200212] ">Bateman 2013</a>; <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a>; <a href="./references#CD010139-bbs2-0004" title="FeldmanG , SilerT , PrasadN , JackD , PiggottS , OwenR , et al. Efficacy and safety of indacaterol 150mcg once‐daily in COPD: a double‐blind randomised 12‐week study. BMC Pulmonary Medicine2010;10:11. ">Feldman 2010</a>; <a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a>; <a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a>; <a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>; <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a>; <a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a>). Five trials with a total of 4133 participants involved a long‐acting beta<sub>2</sub>‐agonist comparison (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0005" title="IzbickiG , ShitritD , RazM , Vilayi‐WeilerZ , FinkG , SchwarzY , et al. Real‐life efficacy of indacaterol and other LABAs in COPD patients in Israel. Chest2014;145(3):431B. [DOI: 10.1378/chest.1829807] ">Izbicki 2014</a>; <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>; <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a>); formoterol was the long‐acting beta<sub>2</sub>‐agonist in <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>, and salmeterol was the long‐acting beta<sub>2</sub>‐agonist in <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>, <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> and <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a>. <a href="./references#CD010139-bbs2-0005" title="IzbickiG , ShitritD , RazM , Vilayi‐WeilerZ , FinkG , SchwarzY , et al. Real‐life efficacy of indacaterol and other LABAs in COPD patients in Israel. Chest2014;145(3):431B. [DOI: 10.1378/chest.1829807] ">Izbicki 2014</a> did not provide data that could be used in this review. One trial did not perform a direct comparison of indacaterol versus placebo or a twice‐daily beta<sub>2</sub>‐agonist but included indacaterol and placebo arms (<a href="./references#CD010139-bbs2-0001" title="BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal 2013 May 30 [Epub ahead of print]. [DOI: 10.1183/09031936.00200212] ">Bateman 2013</a>). For the 75 mcg indacaterol analysis, data were derived from two 12‐week trials with identical methodology (<a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a>; <a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a>). All studies other than <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> were sponsored by Novartis, and at least one author of all published papers was an employee of Novartis. All trials were between 12 and 52 weeks in duration. Participants were recruited across a wide range of centres, predominantly in the United States, Canada, Europe and Asia. Inclusion criteria were similar across all trials. Participants were 40 years of age or older with confirmed COPD, as defined by GOLD criteria; had an FEV<sub>1</sub> of between 30% and 80% predicted; and had at least a 10‐pack‐year smoking history. In all studies other than <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a>, participant characteristics were well matched between intervention and control arms. In most trials, mean FEV<sub>1</sub> was approximately 50% to 55% predicted. <a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a> deliberately enrolled participants with more severe disease, and mean FEV<sub>1</sub> in this trial was approximately 35% predicted in active and control arms. In <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a>, <a href="./references#CD010139-bbs2-0005" title="IzbickiG , ShitritD , RazM , Vilayi‐WeilerZ , FinkG , SchwarzY , et al. Real‐life efficacy of indacaterol and other LABAs in COPD patients in Israel. Chest2014;145(3):431B. [DOI: 10.1378/chest.1829807] ">Izbicki 2014</a> and <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a>, the mean FEV<sub>1</sub> was not explicitly stated. Participants were required to have been on stable doses of maintenance therapy in the six to eight weeks before study commencement. Inhaled corticosteroids were continued at fixed doses. Except when a specific comparison was performed, alternative long‐acting bronchodilators were ceased. Participants with asthma were excluded. Individuals with unstable COPD and those whose condition had recently exacerbated were also generally excluded. Outcomes assessed included a variety of spirometric outcomes, quality of life as measured by St George Respiratory Questionnaire (SGRQ), dyspnoea as measured by the Transitional Dyspnoea Index, adverse events, mortality and exacerbations. The definition of an exacerbation was not standardised across trials, and definitions of exacerbations were not universally reported. In two trials (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a>), an exacerbation was defined as the onset of worsening of one or more respiratory symptom (dyspnoea, cough, sputum purulence or volume or wheeze) for three or more consecutive days requiring an escalation in treatment (administration of systemic steroids, antibiotics or oxygen) and/or a hospital admission or emergency department visit. In two trials (<a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a>; <a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a>), the definition was worsening of two or more major symptoms (dyspnoea, sputum volume or purulence) or worsening of one major and one minor symptom (sore throat, cold, fever without other cause, increased cough or increased wheeze) for at least two consecutive days and requiring treatment with antibiotics and/or steroids. In two trials (<a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>), exacerbations were not included as prespecified outcomes and definitions were not available. However data were supplied upon request by study authors and by Novartis. In <a href="./references#CD010139-bbs2-0004" title="FeldmanG , SilerT , PrasadN , JackD , PiggottS , OwenR , et al. Efficacy and safety of indacaterol 150mcg once‐daily in COPD: a double‐blind randomised 12‐week study. BMC Pulmonary Medicine2010;10:11. ">Feldman 2010</a>, exacerbations were included in a global assessment of adverse events, and data were unavailable for this outcome. In most studies, mixed‐model statistical analyses were performed, with treatment, smoking status and, when relevant, country as fixed effects, and baseline FEV<sub>1</sub> and reversibility as co‐variates. Missing data were generally imputed using last observation carried forward. </p> </section> <section id="CD010139-sec-0063"> <h4 class="title">Excluded studies</h4> <p>Of 23 full‐text articles reviewed, 11 were excluded (see <a href="./references#CD010139-sec-0134" title="">Characteristics of excluded studies</a>). Five were excluded because study duration was less than 12 weeks (<a href="./references#CD010139-bbs2-0014" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. ">Barnes 2010</a>; <a href="./references#CD010139-bbs2-0015" title="BeehKM , WagnerF , KhindriS , DrollmannAF . Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD2011;8(5):340‐5. ">Beeh 2011</a>; <a href="./references#CD010139-bbs2-0020" title="BeehKM , WagnerF , KhindriS , DrollmannAF . Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD2011;8(5):340‐5. ">Khindri 2011</a>; <a href="./references#CD010139-bbs2-0021" title="MagnussenH , VerkindreC , JackD , JadayelD , HenleyM , WoessnerR , et al. Indacaterol once‐daily is equally effective dosed in the evening or morning in COPD. Respiratory Medicine2010;104(12):1869‐76. ">Magnussen 2010</a>; <a href="./references#CD010139-bbs2-0024" title="Van deMaeleB , FabbriLM , MartinC , HortonR , DolkerM , OverendT . Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD2010;7(6):418‐27. ">Van de Maele 2010</a>). Two studies were excluded because open‐label tiotropium was administered in both indacaterol and placebo arms (<a href="./references#CD010139-bbs2-0022" title="MahlerDA , D'UrzoA , BatemanED , OzkanS , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised double‐blind comparison. Thorax2012;67:781‐8. ">Mahler 2012 Study 1</a>; <a href="./references#CD010139-bbs2-0023" title="MahlerDA , D'UrzoA , BatemanED , OzkanS , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised double‐blind comparison. Thorax2012;67:781‐8. ">Mahler 2012 Study 2</a>). One study was a meta‐analysis of three trials already included in the review (<a href="./references#CD010139-bbs2-0019" title="JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. ">Jones 2011</a>). Another study was not a randomised controlled trial (<a href="./references#CD010139-bbs2-0018" title="HatajiO , NaitoM , ItoK , WatanabeF , GabazzaE , TaguchiO . Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. International Journal of COPD2012;8:1‐5. ">Hataji 2013</a>). One study did not compare indacaterol versus placebo or another long‐acting beta<sub>2</sub>‐agonist (<a href="./references#CD010139-bbs2-0016" title="BuhlR , DunnLJ , DisdierC , LassenC , AmosC , HenleyM , et al. Blinded 12‐week comparison of once‐daily indacaterol and tiotropium in COPD. European Respiratory Journal2011;38(4):797‐803. ">Buhl 2011</a>). Another was a 26‐week continuation study of <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a>, in which participants randomly assigned in the original study were asked to consent to continuation, and this was therefore no longer a comparison of participants as randomly assigned (<a href="./references#CD010139-bbs2-0017" title="ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. ">Chapman 2011</a>). The final analysis for this trial included data over the entire 52‐week period encompassed by <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a> and <a href="./references#CD010139-bbs2-0017" title="ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. ">Chapman 2011</a>; therefore to avoid double counting of participants, the two trials could not be combined in the same meta‐analysis. </p> </section> </section> <section id="CD010139-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall risk of bias was judged to be low (see <a href="#CD010139-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD010139-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010139-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010139-sec-0065"> <h4 class="title">Allocation</h4> <p>Randomisation was generally adequate and automated systems were used in most studies. In <a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a>, <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a> and <a href="./references#CD010139-bbs2-0004" title="FeldmanG , SilerT , PrasadN , JackD , PiggottS , OwenR , et al. Efficacy and safety of indacaterol 150mcg once‐daily in COPD: a double‐blind randomised 12‐week study. BMC Pulmonary Medicine2010;10:11. ">Feldman 2010</a>, the method of randomisation was unclear. <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> was judged to be at high risk of selection bias in view of baseline imbalances in this study. </p> </section> <section id="CD010139-sec-0066"> <h4 class="title">Blinding</h4> <p>Blinding was generally sufficient to protect against significant performance and detection bias. <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a> was an open‐label trial, and it is possible that this may have introduced bias. Blinding in <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> was uncertain, as no clear report a placebo inhaler device was provided. </p> </section> <section id="CD010139-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>Outcome reporting was generally adequate, although in some studies handling and reporting of incomplete outcome data were not clear. Rates of dropout were fairly similar across experimental and control arms—generally between 10% and 20% across different studies—with a tendency toward slightly greater loss of participants from placebo arms. It seems unlikely that this has led to significant systematic bias. </p> </section> <section id="CD010139-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Risk of selective reporting bias was generally low. However in <a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a> and <a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a>, a variety of secondary outcomes were incompletely reported and risk of reporting bias was judged to be high. In <a href="./references#CD010139-bbs2-0004" title="FeldmanG , SilerT , PrasadN , JackD , PiggottS , OwenR , et al. Efficacy and safety of indacaterol 150mcg once‐daily in COPD: a double‐blind randomised 12‐week study. BMC Pulmonary Medicine2010;10:11. ">Feldman 2010</a> SGRQ score was not a prespecified outcome. However SGRQ scores were supplied by Novartis upon request. </p> </section> <section id="CD010139-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>None identified.</p> </section> </section> <section id="CD010139-sec-0070"> <h3 class="title" id="CD010139-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD010139-tbl-0001"><b>Summary of findings for the main comparison</b> Indacaterol versus placebo</a>; <a href="./full#CD010139-tbl-0002"><b>Summary of findings 2</b> Indacaterol versus twice‐daily long‐acting beta<sub>2</sub>‐agonists for chronic obstructive pulmonary disease</a> </p> <section id="CD010139-sec-0071"> <h4 class="title">Indacaterol versus placebo</h4> <section id="CD010139-sec-0072"> <h5 class="title">Trough FEV<sub>1</sub> at the end of the dosing interval </h5> <p>Higher scores measured using spirometry indicate improvement in lung function, and 100 mL represents a clinically important difference in FEV<sub>1</sub> (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>). Ten trials contributed data on this outcome from 5001 participants. Compared with placebo, the mean trough FEV<sub>1</sub> was significantly greater with indacaterol (MD 149.11, 95% CI 137.09 to 161.12) (<a href="./references#CD010139-fig-0005" title="">Analysis 1.1</a>). The trough FEV<sub>1</sub> was significantly greater for indacaterol than for placebo for 75 mcg (MD 130.00 mL, 95% CI 101.72 to 158.28), 150 mcg (MD 146.52 mL, 95% CI 129.94 to 163.11), 300 mcg (MD 169.27 mL, 95% CI 144.52 to 194.02) and 600 mcg doses (MD 150.00 mL, 95% CI 100.62 to 199.38). Significant heterogeneity was identified in the 300 mcg analysis (I<sup>2</sup> = 53%). This was largely a consequence of results from <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a>. This study was a much smaller study than the Novartis‐sponsored trials and was at higher risk of bias (<a href="#CD010139-fig-0002">Figure 2</a>). In addition only raw end‐of‐study data were available, and these showed significantly overestimates of treatment effect in this study due to poorly matched experimental and placebo arms at trial commencement (baseline FEV<sub>1</sub> was 1.22 L in the placebo group and 1.78 L in the indacaterol group at study commencement). Sensitivity analysis was performed by excluding <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> from the 300 mcg analysis. No significant change in the estimate of treatment effect was noted for the 300 mcg dose of indacaterol compared with placebo (MD 167.78 mL, 95% CI 142.98 to 192.57). Exclusion of <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> from the entire analysis similarly had no significant impact on the overall estimate of treatment effect of indacaterol compared with placebo (MD 148.74 mL, 95% CI 136.72 to 160.76). Subgroup analysis of trials of less than 24 weeks (MD 148.99 mL, 95% CI 129.11 to 168.86) and 24 weeks or longer (MD 149.26 mL, 95% CI 134.01 to 164.51) demonstrated significant increases in trough FEV<sub>1</sub> with indacaterol compared with placebo (<a href="./references#CD010139-fig-0006" title="">Analysis 1.2</a>). Heterogeneity in subgroup analysis of trials of less than 24‐weeks was significant (I<sup>2</sup> = 66). Statistical heterogeneity was largely explained by the results reported by <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a>, which as discussed above was a small study with less robust methodology.The estimate of treatment effect in <a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a> was also slightly greater than in the remaining three studies.The reason for this is unclear, as aside from <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a>, all studies had similar trial methodologies and statistical analyses, and were judged to be generally at low risk of bias. </p> <p>Data were insufficient for planned subgroup analysis by GOLD class severity.</p> </section> <section id="CD010139-sec-0073"> <h5 class="title">Quality of life</h5> <p>Lower scores measured using the SGRQ indicate improvement in quality of life; four units represents a clinically important difference (<a href="./references#CD010139-bbs2-0037" title="JonesPW . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. European Respiratory Journal2002;19(3):398‐404. ">Jones 2002</a>). Ten trials contributed data from 4938 participants for this outcome. Compared with placebo, the mean SGRQ score was significantly lower with indacaterol (MD ‐3.60, 95% CI ‐4.36 to ‐2.83) (<a href="./references#CD010139-fig-0007" title="">Analysis 1.3</a>). Mean SGRQ scores were significantly lower with indacaterol than with placebo for 75 mcg (MD ‐3.70, 95% CI ‐5.66 to ‐1.74), 150 mcg (MD ‐3.43, 95% CI ‐4.53 to ‐2.32), 300 mcg (MD ‐3.49, 95% CI ‐4.94 to ‐2.03) and 600 mcg doses (MD ‐4.60, 95% CI ‐7.07 to ‐2.13). No significant statistical heterogeneity was noted. Sensitivity analysis was performed by removing <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> because of concerns over methodological quality. This did not significantly alter the estimate of effect for indacaterol compared with placebo overall, nor for the 300 mcg subgroup analysis. Planned subgroup analysis by trial duration demonstrated slightly greater improvement in mean SGRQ for trials of less than 24 weeks (MD ‐4.11, 95% CI ‐5.60 to ‐2.62) than for trials 24 weeks or longer in duration (MD ‐3.15, 95% CI ‐4.12 to ‐2.19), but the difference between subgroups was not statistically significant (test for subgroup differences: Chi² = 1.11, df = 1 (P value 0.25), I² = 10.3%) (<a href="./references#CD010139-fig-0008" title="">Analysis 1.4</a>). </p> <p>Data were insufficient for planned subgroup analysis by GOLD class severity.</p> </section> <section id="CD010139-sec-0074"> <h5 class="title">Number of participants with a clinically significant improvement in quality of life</h5> <p>Compared with placebo, the odds of achieving an improvement in SGRQ score of at least four points overall were significantly greater with indacaterol (OR 1.64, 95% CI 1.46 to 1.85) (<a href="./references#CD010139-fig-0009" title="">Analysis 1.5</a>). We estimate that for 1000 participants with stable COPD treated for 12 to 52 weeks, 121 more participants (95% CI 94 to 151) would experience a clinically significant improvement in quality of life with indacaterol than with placebo (as shown in the Cates plot in <a href="#CD010139-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010139-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Cates plot. Participants with a clinically significant improvement in quality of life with indacaterol compared with placebo." data-id="CD010139-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cates plot. Participants with a clinically significant improvement in quality of life with indacaterol compared with placebo. </p> </div> </div> </div> <p>Compared with placebo, the odds of achieving an improvement in SGRQ score of at least four points were significantly greater for 75 mcg indacaterol (OR 1.73, 95% CI 1.24 to 2.41), 150 mcg indacaterol (OR 1.67, 95% CI 1.41 to 1.98), 300 mcg indacaterol (OR 1.46, 95% CI 1.15 to 1.85) and 600 mcg indacaterol doses (OR 1.95, 95% CI 1.30 to 2.94). No significant difference between subgroups was noted (test for subgroup differences: Chi² = 1.78, df = 3 (P value 0.62), I² = 0%). Planned subgroup analysis by trial duration demonstrated slightly increased odds of achieving an improvement in SGRQ of at least four points in trials of less than 24 weeks (OR 1.90, 95% CI 1.51 to 2.38) compared with trials 24 weeks or longer (OR 1.45, 95% CI 1.26 to 1.67), and the difference between subgroups was significant (test for subgroup differences: Chi² = 3.86, df = 1 (P value 0.02), I² = 74.1%) (<a href="./references#CD010139-fig-0010" title="">Analysis 1.6</a>). </p> <p>Data were insufficient for planned subgroup analysis by GOLD class severity.</p> </section> <section id="CD010139-sec-0075"> <h5 class="title">Peak FEV<sub>1</sub> </h5> <p>Six trials contributed data on this outcome from 1657 participants. Overall peak FEV<sub>1</sub> was significantly greater with indacaterol than with placebo (MD 181.21 mL, 95% CI 129.10 to 233.32) (<a href="./references#CD010139-fig-0013" title="">Analysis 1.9</a>). Peak FEV<sub>1</sub> was significantly greater for indacaterol than for placebo for 75 mcg (MD 196.56 mL, 95% CI 107.15 to 285.98), 150 mcg (MD 200.91 mL, 95% CI 111.71 to 290.12) and 300 mcg doses (MD 173.50 mL, 95% CI 69.92 to 277.09). No statistically significant difference in peak FEV<sub>1</sub> was noted with indacaterol compared with placebo for the 600 mcg dose (MD 30.00 mL, 95% CI ‐172.77 to 232.77). Data for the 600 mcg comparison were derived from one 52‐week trial (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>), whereas data for the other comparisons came from trials of between 12 weeks' and 26 weeks' duration. Overall no significant statistical heterogeneity was noted (I<sup>2</sup> = 0%). </p> </section> <section id="CD010139-sec-0076"> <h5 class="title">Dyspnoea</h5> <p>Higher scores on the Transitional Dyspnoea Index (TDI) indicate improvement in breathlessness; one unit represents a clinically important difference (<a href="./references#CD010139-bbs2-0043" title="WitekTJ , MahlerDA . Minimal important difference of the transition dyspnoea index in a multinational clinical trial. European Respiratory Journal2003;21(2):267‐72. ">Witek 2003</a>). Eight trials contributed data from 4722 participants for this outcome. Compared with placebo, overall mean TDI score was significantly higher with indacaterol (MD 1.00, 95% CI 0.82 to 1.17) (<a href="./references#CD010139-fig-0011" title="">Analysis 1.7</a>). Mean TDI scores were significantly greater with indacaterol than with placebo for 75 mcg (MD 0.77, 95% CI 0.27 to 1.27), 150 mcg (MD 0.96, 95% CI 0.70 to 1.22), 300 mcg (MD 1.13, 95% CI 0.83 to 1.43) and 600 mcg doses (MD 0.98, 95% CI 0.51 to 1.45). Statistical heterogeneity was significant in the 75 mcg subgroup analysis (I<sup>2</sup> = 54%), which included two trials of identical methodology and participants with similar demographics. However overall statistical heterogeneity was not significant. </p> </section> <section id="CD010139-sec-0077"> <h5 class="title">Number of participants experiencing a clinically significant improvement in dyspnoea</h5> <p>Compared with placebo, the odds of achieving an improvement in TDI score greater than or equal to 1 overall were significantly greater with indacaterol (OR 1.96, 95% CI 1.73 to 2.22) (<a href="./references#CD010139-fig-0012" title="">Analysis 1.8</a>). We estimate that for 1000 participants with stable COPD treated for 12 to 52 weeks, 166 more participants (95% CI 136 to 196) would have a clinically significant improvement in dyspnoea with indacaterol than without (<a href="#CD010139-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010139-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Cates plot. Participants with a clinically significant improvement in dyspnoea with indacaterol compared with placebo." data-id="CD010139-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cates plot. Participants with a clinically significant improvement in dyspnoea with indacaterol compared with placebo. </p> </div> </div> </div> <p>Compared with placebo, the odds of achieving an improvement in TDI score of at least one point were significantly greater for 75 mcg indacaterol (OR 1.76, 95% CI 1.26 to 2.45), 150 mcg indacaterol (OR 1.87, 95% CI 1.56 to 2.24), 300 mcg indacaterol (OR 2.25, 95% CI 1.81 to 2.81) and 600 mcg doses (OR 1.80, 95% CI 1.20 to 2.70). Overall no significant statistical heterogeneity was observed. Heterogeneity was significant in the 300 mcg comparison, which included four trials (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a>; <a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a>; <a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a>). The odds of achieving a significant improvement in TDI were lower in <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> and <a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a> than in <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a> and <a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a>. The reasons for this are unclear. Trial participants had similar degrees of airflow limitation (mean FEV<sub>1</sub> was generally 50% predicted)<b>,</b> trial methodology was similar, all were judged to be at relatively low risk for significant systematic bias and all used similar mixed‐models statistical approaches to data analysis. The effect of statistical heterogeneity was explored by performing a random‐effects analysis, which did not result in a significantly different point estimate of effect for this outcome. </p> </section> <section id="CD010139-sec-0078"> <h5 class="title">Serious adverse events</h5> <p>Nine trials contributed data on serious adverse events from 6065 participants. Overall no statistically significant difference in the odds of experiencing a serious adverse event was noted for indacaterol compared with placebo (OR 1.00,95% CI 0.82 to 1.23). Subgroup analysis by dose did not demonstrate significant differences between placebo and indacaterol 75 mcg (OR 0.60, 95% CI 0.24 to 1.46), indacaterol 150 mcg (OR 1.01, 95% CI 0.75 to 1.37), indacaterol 300 mcg (OR 1.04, 95% CI 0.74 to 1.45) and indacaterol 600 mcg (OR 1.09, 95% CI 0.65 to 1.83) (test for subgroup differences: Chi² = 3.07, df = 3 (P value 0.38), I² = 2.2%) (<a href="./references#CD010139-fig-0014" title="">Analysis 1.10</a>). The confidence intervals are too wide to rule out important differences in serious adverse events between indacaterol and placebo. </p> </section> <section id="CD010139-sec-0079"> <h5 class="title">Mortality</h5> <p>Nine trials contributed data on mortality from 5694 participants. Overall no significant difference was observed in the odds of mortality with indacaterol compared with placebo (OR 0.42, 95% CI 0.16 to 1.08). Subgroup analysis by dose did not demonstrate significant differences between placebo and indacaterol 75 mcg (OR 0.19, 95% CI 0.01 to 4.07), indacaterol 150 mcg (OR 0.86, 95% CI 0.23 to 3.16), indacaterol 300 mcg (OR 0.25, 95% CI 0.02 to 2.72) and indacaterol 600 mcg (OR 0.10, 95% CI 0.00 to 2.11) (test for subgroup differences: Chi² = 2.40, df = 3 (P value 0.49), I² = 0%) (<a href="./references#CD010139-fig-0015" title="">Analysis 1.11</a>). The confidence intervals are too wide to rule out important differences in mortality between indacaterol and twice‐daily beta<sub>2</sub>‐agonists. </p> </section> <section id="CD010139-sec-0080"> <h5 class="title">Number of participants experiencing at least one protocol‐defined exacerbation</h5> <p>Compared with placebo, the overall odds of experiencing at least one exacerbation were significantly less with indacaterol (OR 0.81, 95% CI 0.70 to 0.94). Subgroup analysis by dose did not demonstrate significant differences between indacaterol 75 mcg (OR 0.85, 95% CI 0.49 to 1.45), 150 mcg (OR 0.82, 95% CI 0.66 to 1.02), 300 mcg (OR 0.84, 95% CI 0.65 to 1.09) and 600 mcg (OR 0.74, 95% CI 0.51 to 1.06) (test for subgroup differences: Chi² = 0.37, df = 3 (P value 0.95), I² = 0%) (<a href="./references#CD010139-fig-0016" title="">Analysis 1.12</a>). </p> </section> </section> <section id="CD010139-sec-0081"> <h4 class="title">Indacaterol versus alternative twice‐daily beta<sub>2</sub>‐agonists </h4> <section id="CD010139-sec-0082"> <h5 class="title">Trough FEV<sub>1</sub> at the end of the dosing interval </h5> <p>Higher scores measured using spirometry indicate an improvement in lung function, and 100 mL represents a clinically important difference in FEV<sub>1</sub> (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>). Four trials contributed data on this outcome from 4708 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Compared with alternative twice‐daily beta<sub>2</sub>‐agonists, the mean trough FEV<sub>1</sub> was significantly greater with indacaterol (MD 73.76 mL, 95% CI 57.33 to 90.19) (<a href="./references#CD010139-fig-0017" title="">Analysis 2.1</a>). The trough FEV<sub>1</sub> was significantly greater for indacaterol compared with twice‐daily beta<sub>2</sub>‐agonists for 150 mcg (MD 62.56 mL, 95% CI 42.71 to 82.40), 300 mcg (MD 97.17 mL, 95% CI 60.51 to 133.83) and 600 mcg doses (MD 100.00 mL, 95% CI 51.21 to 148.79). Trough FEV<sub>1</sub> was slightly greater for the 300 mcg and 600 mcg doses than for the 150 mcg dose, but this finding was not statistically significant (test for subgroup differences: Chi² = 3.90, df = 2 (P value 0.14), I² = 48.7%). Overall no significant heterogeneity was observed (I<sup>2</sup> = 15%).<sup>.</sup> Subgroup analysis by type of twice‐daily beta<sub>2</sub>‐agonist demonstrated a significant increase in FEV<sub>1</sub> for indacaterol compared with salmeterol (MD 64.50 mL, 95% CI 45.79 to 83.20). Data for the formoterol comparison were derived from one trial only (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>), which compared 600 mcg indacaterol versus placebo. This study demonstrated a significant improvement in trough FEV<sub>1</sub> with indacaterol compared with formoterol (MD 98.19 mL, 95% CI 68.88 to 127.50). Subgroup analysis by trial duration demonstrated a significantly increased FEV<sub>1</sub> with indacaterol compared with alternative twice‐daily beta<sub>2</sub>‐agonists for trials 24 weeks or longer (MD 122.98 mL, 95% CI 102.37 to 143.59) and for trials of less than 24 weeks (MD 60.00 mL, 95% CI 37.00 to 83.00) (<a href="./references#CD010139-fig-0018" title="">Analysis 2.2</a>). Heterogeneity in analysis of trials 24 weeks or longer was significant (I<sup>2</sup> = 73%). The estimate of effect from <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> was significantly greater than in the other three studies. The reasons for this are unclear, although it is possible that the modified intention‐to‐treat analysis used in this study (participants from six sites were excluded for non‐conformance with good clinical practice) may have contributed. Only one study (<a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>) was less than 24 weeks in duration. </p> <p>Data were insufficient for planned subgroup analysis by GOLD class severity.</p> </section> <section id="CD010139-sec-0083"> <h5 class="title">Quality of life</h5> <p>Lower scores measured using the SGRQ indicate improvement in quality of life; four units represents a clinically important difference (<a href="./references#CD010139-bbs2-0037" title="JonesPW . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. European Respiratory Journal2002;19(3):398‐404. ">Jones 2002</a>). Two trials contributed data on this outcome from 1523 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Overall no statistically significant differences in mean SGRQ scores were noted between indacaterol and twice‐daily beta<sub>2</sub>‐agonists (MD ‐0.81, 95% CI ‐2.28 to 0.66) (<a href="./references#CD010139-fig-0019" title="">Analysis 2.3</a>). <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> was the only trial that contributed data to the 150 mcg comparison, whilst <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> was the only trial that performed 300 mcg and 600 mcg comparisons. No significant differences were noted between indacaterol and twice‐daily beta<sub>2</sub>‐agonists for the 150 mcg (MD ‐1.20, 95% CI ‐3.42 to 1.02), 300 mcg (MD ‐0.50, 95% CI ‐3.27 to 2.27) and 600 mcg doses (MD ‐0.50, 95% CI ‐3.27 to 2.27). Both trials were 24 weeks or longer in duration. Therefore subgroup analysis by trial duration was not performed. Subgroup analysis by type of twice‐daily beta<sub>2</sub>‐agonist demonstrated no significant differences between indacaterol and salmeterol (MD ‐1.20, 95% CI ‐3.42 to 1.02) or between indacaterol and formoterol (MD 0.42, 95% CI ‐1.21 to 2.05). </p> <p>Data were insufficient for planned subgroup analysis by GOLD class severity.</p> </section> <section id="CD010139-sec-0084"> <h5 class="title">Number of participants with a clinically significant improvement in quality of life</h5> <p>Two trials contributed data on this outcome from 1520 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Overall no significant difference was observed between indacaterol and twice‐daily beta<sub>2</sub>‐agonists in the odds of achieving a clinically significant improvement in SGRQ (OR 1.07, 95% CI 0.87 to 1.32) (<a href="./references#CD010139-fig-0021" title="">Analysis 2.5</a>). No significant differences were noted between indacaterol and alternative twice‐daily beta<sub>2</sub>‐agonists in the odds of achieving a clinically significant improvement in quality of life with 150 mcg (OR 1.17, 95% CI 0.85 to 1.61), 300 mcg (OR 0.93, 95% CI 0.63 to 1.37) and 600 mcg doses (OR 1.09, 95% CI 0.74 to 1.61). Both trials were 24 weeks or longer in duration (<a href="./references#CD010139-fig-0022" title="">Analysis 2.6</a>). Therefore subgroup analysis by trial duration was not performed. </p> <p>Data were insufficient for planned subgroup analysis by GOLD class severity.</p> </section> <section id="CD010139-sec-0085"> <h5 class="title">Peak FEV<sub>1</sub> </h5> <p>Two trials contributed data on this outcome from 491 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. No significant difference was observed between indacaterol and alternative twice‐daily beta<sub>2</sub>‐agonists with respect to peak FEV<sub>1</sub> (MD 4.68, 95% CI ‐93.79 to 103.16) (<a href="./references#CD010139-fig-0025" title="">Analysis 2.9</a>). Subgroup analysis by dose demonstrated no significant differences between indacaterol and alternative twice‐daily beta<sub>2</sub>‐agonists for the 150 mcg (MD 40.00, 95% CI ‐113.72 to 193.72), 300 mcg (MD ‐30.00, 95% CI ‐212.29 to 152.29) and 600 mcg doses (MD ‐10.00, 95% CI ‐190.45 to 170.45). No significant heterogeneity was observed (I<sup>2</sup> = 0%). </p> </section> <section id="CD010139-sec-0086"> <h5 class="title">Dyspnoea</h5> <p>Higher scores on the TDI indicate improvement in breathlessness; one unit represents a clinically important difference (<a href="./references#CD010139-bbs2-0043" title="WitekTJ , MahlerDA . Minimal important difference of the transition dyspnoea index in a multinational clinical trial. European Respiratory Journal2003;21(2):267‐72. ">Witek 2003</a>). Three trials contributed data on this outcome from 2404 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists, overall mean TDI score was significantly greater with indacaterol (MD 0.54, 95% CI 0.30 to 0.79) (<a href="./references#CD010139-fig-0023" title="">Analysis 2.7</a>). Subgroup analysis by dose demonstrated a significant increase in TDI with indacaterol 150 mcg compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists (MD 0.66, 95% CI 0.37 to 0.95). No significant differences were observed between indacaterol and twice‐daily long‐acting beta<sub>2</sub>‐agonists for 300 mcg (MD 0.19, 95% CI ‐0.46 to 0.84) and 600 mcg doses (MD 0.30, 95% CI ‐0.35 to 0.95). The 150 mcg comparison involved two trials (<a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>) of 12 weeks' and 26 weeks' duration, respectively; both used salmeterol as the active comparator. Data on the 300 mcg and 600 mcg doses were received from only one 52‐week trial (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>), which used formoterol as the active comparator. </p> </section> <section id="CD010139-sec-0087"> <h5 class="title">Number of participants experiencing a clinically significant improvement in dyspnoea</h5> <p>Three trials contributed data on this outcome from 2536 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Overall, no significant differences were observed in the odds of experiencing an improvement in TDI greater than or equal to one point with indacaterol compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists (OR 1.11, 95% CI 0.94 to 1.32) (<a href="./references#CD010139-fig-0024" title="">Analysis 2.8</a>). Subgroup analysis by dose demonstrated no significant differences between indacaterol and alternative twice‐daily beta<sub>2</sub>‐agonists for the 150 mcg (OR 1.21, 95% CI 0.98 to 1.50), 300 mcg (OR 0.87, 95% CI 0.59 to 1.29) and 600 mcg doses (OR 1.06, 95% CI 0.72 to 1.58). Heterogeneity in the 150 mcg comparison was significant (I<sup>2</sup> = 65%). <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a> demonstrated significant improvement in the odds of achieving an improvement in TDI greater than or equal to one point, whereas <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> and <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> did not. The reason for the difference between <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a> and <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> for this particular outcome is unclear, especially given the similar improvements in mean TDI noted in these two studies. Both were large trials recruiting more than 1000 participants; both used salmeterol as the active comparator, had similar trial methodologies and statistical analyses, recruited participants from generally similar geographic locations and enrolled participants with similar baseline characteristics. Both trials were judged to be at generally low risk of bias. </p> </section> <section id="CD010139-sec-0088"> <h5 class="title">Serious adverse events</h5> <p>Four trials contributed data on serious adverse events from 3266 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists, no statistically significant difference in serious adverse events was reported with indacaterol (OR 1.02, 95% CI 0.79 to 1.32) (<a href="./references#CD010139-fig-0026" title="">Analysis 2.10</a>). No significant differences were observed between twice‐daily beta<sub>2</sub>‐agonists and indacaterol 150 mcg (OR 1.44, 95% CI 0.92 to 2.25), indacaterol 300 mcg (OR 1.00, 95% CI 0.66 to 1.52) and indacaterol 600 mcg (OR 0.71, 95% CI 0.45 to 1.13). The confidence intervals are too wide to rule out important differences in serious adverse events between indacaterol and twice‐daily beta<sub>2</sub>‐agonists. </p> </section> <section id="CD010139-sec-0089"> <h5 class="title">Mortality</h5> <p>Four trials contributed data on mortality from 3266 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists, no significant differences in mortality were noted with indacaterol (OR 1.00, 95% CI 0.31 to 3.28) (<a href="./references#CD010139-fig-0027" title="">Analysis 2.11</a>). No significant differences were reported between twice‐daily beta<sub>2</sub>‐agonists and indacaterol 150 mcg (OR 2.35, 95% CI 0.35 to 15.98), indacaterol 300 mcg (OR 0.82, 95% CI 0.11 to 6.27) and indacaterol 600 mcg (OR 0.17, 95% CI 0.01 to 4.18). The confidence intervals are too wide to rule out important differences in mortality between indacaterol and twice‐daily beta<sub>2</sub>‐agonists. </p> </section> <section id="CD010139-sec-0090"> <h5 class="title">Number of participants experiencing at least one protocol‐defined exacerbation</h5> <p>Two trials contributed data on this outcome from 1869 participants. Formoterol and salmeterol were compared with 150 mcg, 300 mcg and 600 mcg doses of indacaterol. Compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists, no significant differences were observed in the odds of experiencing at least one exacerbation with indacaterol (OR 1.04, 95% CI 0.84 to1.29) (<a href="./references#CD010139-fig-0028" title="">Analysis 2.12</a>). Compared with twice‐daily beta<sub>2</sub>‐agonists, no significant differences were observed in the odds of experiencing at least one exacerbation with indacaterol 150 mcg (OR 1.21, 95% CI 0.80 to 1.82), indacaterol 300 mcg (OR 1.06, 95% CI 0.74 to 1.53) and indacaterol 600 mcg (OR 0.90, 95% CI 0.62 to 1.30). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010139-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010139-sec-0091"></div> <section id="CD010139-sec-0092"> <h3 class="title" id="CD010139-sec-0092">Summary of main results</h3> <section id="CD010139-sec-0093"> <h4 class="title">Indacaterol versus placebo</h4> <p>Compared with placebo, once‐daily dosing with indacaterol results in statistically significant and clinically relevant increases in trough forced expiratory volume in one second (FEV<sub>1</sub>) (<a href="./references#CD010139-fig-0005" title="">Analysis 1.1</a>). Subgroup analysis by dose demonstrated similar improvements in trough FEV<sub>1</sub> across 75 mcg, 150 mcg, 300 mcg and 600 mcg doses. All exceeded the minimum clinically relevant difference of 100 mL (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>). Planned subgroup analysis by trial duration demonstrated a sustained response to indacaterol over 52 weeks, with similar improvements in trough FEV<sub>1</sub> reported in trials of less than 24 weeks and in 24 weeks or longer in duration (<a href="./references#CD010139-fig-0006" title="">Analysis 1.2</a>). </p> <p>Quality of life was improved for a significant number of participants with indacaterol compared with placebo. The overall mean St George Respiratory Questionnaire (SGRQ) score was lower with indacaterol (<a href="./references#CD010139-fig-0007" title="">Analysis 1.3</a>). Similar responses were noted across 75 mcg, 150 mcg, 300 mcg and 600 mcg doses. Although the overall point estimate of effect did not reach the accepted four unit minimum clinically important difference for an improvement in quality of life (<a href="./references#CD010139-bbs2-0037" title="JonesPW . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. European Respiratory Journal2002;19(3):398‐404. ">Jones 2002</a>), the odds of achieving an SGRQ score improvement of four or more points were significantly greater with indacaterol than with placebo over 12 to 52 weeks. We estimate that for 1000 participants with stable chronic obstructive pulmonary disease (COPD), 121 more participants would experience a clinically significant improvement in quality of life with indacaterol than without (<a href="#CD010139-fig-0003">Figure 3</a>). The odds of a clinically significant improvement in quality of life were similar with all four doses of indacaterol. </p> <p>Other planned primary outcome analyses were exacerbation rates and proportions of people with a clinically significant deterioration in quality of life. Data were insufficient to include these outcomes in a meta‐analysis. </p> <p>Secondary outcomes included mean dyspnoea scores, proportions of participants with a clinically significant improvement in dyspnoea, peak FEV<sub>1</sub>, serious adverse events and mortality. As data were insufficient for a comparison of exacerbation rates, we also compared the number of participants experiencing at least one exacerbation as a further post hoc secondary analysis. </p> <p>Overall mean dyspnoea scores (<a href="./references#CD010139-fig-0011" title="">Analysis 1.7</a>), odds of achieving a clinically significant improvement in dyspnoea (<a href="./references#CD010139-bbs2-0043" title="WitekTJ , MahlerDA . Minimal important difference of the transition dyspnoea index in a multinational clinical trial. European Respiratory Journal2003;21(2):267‐72. ">Witek 2003</a>) (<a href="./references#CD010139-fig-0012" title="">Analysis 1.8</a>) and peak FEV<sub>1</sub> (<a href="./references#CD010139-fig-0013" title="">Analysis 1.9</a>) were all significantly improved with indacaterol compared with placebo. We estimate that for 1000 participants with stable COPD, 166 more participants would have a clinically significant improvement in dyspnoea with indacaterol than with placebo over 12 to 52 weeks (<a href="#CD010139-fig-0004">Figure 4</a>). </p> <p>The overall odds of experiencing at least one exacerbation were significantly less with indacaterol than with placebo (<a href="./references#CD010139-fig-0016" title="">Analysis 1.12</a>). Many trials were of short duration, and the definition of exacerbation was not standardised across trials. Furthermore, it was not possible to measure exacerbation rates as had been planned because data were insufficient. Finally, for each tested dose, a statistically significant reduction in the number of participants experiencing at least one exacerbation was not demonstrated. Therefore, whilst inspection of the forest plot does not suggest a significant dose‐response effect, it is difficult to be confident about the true effect of indacaterol on exacerbations for any individual dose. Nonetheless, we estimate that overall, for 1000 participants treated with indacaterol for stable COPD, 34 fewer participants would experience at least one exacerbation over a treatment period of 12 to 52 weeks compared with untreated participants. </p> <p>No significant difference was noted between indacaterol and placebo in the number of participants suffering a serious adverse event (<a href="./references#CD010139-fig-0014" title="">Analysis 1.10</a>) or mortality (<a href="./references#CD010139-fig-0015" title="">Analysis 1.11</a>), but the confidence intervals are too wide to rule out important differences. </p> <p>Other planned secondary outcomes were 24‐hour area under the curve FEV<sub>1</sub>, peak forced vital capacity (FVC) and number of participants experiencing clinically significant deterioration in dyspnoea. Data were insufficient for analysis of these outcomes. </p> </section> <section id="CD010139-sec-0094"> <h4 class="title">Indacaterol versus twice‐daily long‐acting beta<sub>2</sub>‐agonists (LABAs) </h4> <p>Fewer data were available for the comparison of indacaterol versus alternative long‐acting beta<sub>2</sub>‐agonists, and only four trials overall contributed data (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>; <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a>). </p> <p>Compared with twice‐daily beta<sub>2</sub>‐agonists, trough FEV<sub>1</sub> was numerically greater with indacaterol (<a href="./references#CD010139-fig-0017" title="">Analysis 2.1</a>), although this did not exceed the generally accepted minimal clinically important difference (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>). Similar improvements were seen with indacaterol at 150 mcg, 300 mcg and 600 mcg doses. A sustained response to indacaterol was once again demonstrated, with improvements in trough FEV<sub>1</sub> reported with indacaterol in trials greater than and less than 24 weeks in duration (<a href="./references#CD010139-fig-0018" title="">Analysis 2.2</a>). Subgroup analysis by type of twice‐daily beta<sub>2</sub>‐agonist demonstrated small and probably clinically irrelevant improvements in trough FEV<sub>1</sub> in the formoterol comparison than in the salmeterol comparison, although only <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> involved a formoterol comparison. </p> <p>Overall, quality of life was not significantly different with indacaterol compared with twice‐daily beta<sub>2</sub>‐agonists, and no significant differences were demonstrated in terms of mean SGRQ scores (<a href="./references#CD010139-fig-0019" title="">Analysis 2.3</a>) or in the proportion of participants achieving a clinically significant improvement in SGRQ (<a href="./references#CD010139-fig-0021" title="">Analysis 2.5</a>) (<a href="./references#CD010139-bbs2-0037" title="JonesPW . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. European Respiratory Journal2002;19(3):398‐404. ">Jones 2002</a>). Only two trials contributed quality of life data (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>); therefore meaningful subgroup analysis is not possible. </p> <p>Other planned primary outcome analyses included exacerbation rates and proportions of people with a clinically significant deterioration in quality of life. Data were insufficient for inclusion of these outcomes in a meta‐analysis. </p> <p>Secondary outcomes included mean dyspnoea scores, proportions of participants with a clinically significant improvement in dyspnoea, peak FEV<sub>1</sub>, serious adverse events and mortality. As in the placebo comparison, data were insufficient for a comparison of exacerbation rates, and so the number of participants experiencing at least one exacerbation was examined as a further post hoc secondary analysis. </p> <p>The overall mean dyspnoea score was significantly greater with indacaterol than with twice‐daily beta<sub>2</sub>‐agonists, but this finding did not exceed the minimum clinically important difference (<a href="./references#CD010139-bbs2-0043" title="WitekTJ , MahlerDA . Minimal important difference of the transition dyspnoea index in a multinational clinical trial. European Respiratory Journal2003;21(2):267‐72. ">Witek 2003</a>) (<a href="./references#CD010139-fig-0023" title="">Analysis 2.7</a>). The odds of achieving a clinically significant improvement in dyspnoea were not statistically significantly different with indacaterol than with twice‐daily beta<sub>2</sub>‐agonists (<a href="./references#CD010139-fig-0024" title="">Analysis 2.8</a>). In the 150 mcg comparison (<a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>; <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>), a statistically significant improvement in mean Transitional Dyspnoea Index (TDI) was seen with indacaterol compared with salmeterol, although this was likely to have been clinically irrelevant. In these two trials, the odds of achieving a clinically significant improvement in dyspnoea were increased only in <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a>. The reason for the discrepancy in this outcome between <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a> and <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> is unclear. Both trials used similar methodology, enrolled participants with similar degrees of airflow limitation and were believed to be at overall relatively low risk of bias. Only one study examined 300 mcg and 600 mcg dose comparisons (<a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>). No significant difference in mean TDI or in the odds of achieving a clinically significant improvement in dyspnoea was noted at 300 mcg or 600 mcg doses. The major methodological difference between the 150 mcg comparison and the 300 mcg and 600 mcg comparisons was the use of formoterol in <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> and salmeterol in <a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a> and <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a>. In addition the former was a 52‐week study, whereas the latter two were trials of 6 months' duration or less. Given the limited number of trials available, significant caution should be applied in drawing any conclusions from subgroup analyses for these outcomes. </p> <p>No significant differences were noted in the odds of experiencing at least one exacerbation, the odds of a serious adverse event or mortality between indacaterol and twice‐daily beta<sub>2</sub>‐agonists, either overall or within any of the subgroups by dose, although again the confidence intervals are too wide to rule out important differences. </p> <p>Other planned secondary outcomes were 24‐hour area under the curve FEV<sub>1</sub>, peak FVC and number of participants experiencing a clinically significant deterioration in dyspnoea. Data were insufficient for analysis of these outcomes. </p> </section> </section> <section id="CD010139-sec-0095"> <h3 class="title" id="CD010139-sec-0095">Overall completeness and applicability of evidence</h3> <section id="CD010139-sec-0096"> <h4 class="title">Indacaterol versus placebo</h4> <p>A strong body of evidence is based on a total of 9961 participants overall. All trials aside from <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> were sponsored by the manufacturer, and inclusion and exclusion criteria were similar. All trials assessed participants with stable COPD across a range of spirometric severities; mean FEV<sub>1</sub> was approximately 50% predicted in most trials. One trial specifically enrolled participants with severe disease, and mean FEV<sub>1</sub> was 35% predicted (<a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a>). Broad international recruitment was seen across these studies, with participants enrolled predominantly from the United States, Canada, Europe, India, Asia and China. It is therefore likely that the results could be generalised to most symptomatic patients with stable COPD and a postbronchodilator FEV<sub>1</sub> of between 30% and 80% predicted. Patients with a diagnosis of asthma, those requiring long‐term oxygen therapy and those with concomitant pulmonary disease were generally excluded from trials, and results should be extrapolated to such patients with caution. In addition patients with diabetes, active malignancy, history of long QT syndrome or prolonged QTc were generally excluded. Four doses were compared with placebo: 75 mcg, 150 mcg, 300 mcg and 600 mcg. Most of the data have been derived from trials assessing 150 mcg and 300 mcg doses of indacaterol. For 75 mcg, two 12‐week trials of identical design were conducted, and for the 600 mcg comparison, one 52‐week trial was completed. Therefore relatively fewer data have been reported for these doses. </p> <p>Fewer data were also found for comparisons with alternative long‐acting beta<sub>2</sub>‐agonists, with only four trials contributing to final analyses. Results for these outcomes therefore should also be interpreted with some caution. </p> </section> </section> <section id="CD010139-sec-0097"> <h3 class="title" id="CD010139-sec-0097">Quality of the evidence</h3> <p>The evidence was generally of good quality. All included data were reported by randomised controlled trials, with generally limited potential for significant bias. Trials demonstrated similar estimates of treatment effects in the same direction for primary outcomes. When significant heterogeneity was identified, this was often explained by differences in the methodological quality of included trials. In a few select instances, statistical heterogeneity was difficult to explain, with relevant trials having similar inclusion and exclusion criteria, enrolling participants with similar severity of disease and using similar methodology and statistical approaches. <a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> was a small study that was judged to be of lower methodological quality. The method used for random sequence generation, allocation concealment and blinding of participants and personnel was not specified. In <a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a> and <a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a>, some predefined secondary endpoints were not published, although outcomes of interest were made available by the manufacturer. <a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a> was an open‐label trial with significant potential for bias. Finally, it is possible that in <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>, exclusion of participants from six investigator sites for non‐conformance with good clinical practice may have introduced bias. </p> </section> <section id="CD010139-sec-0098"> <h3 class="title" id="CD010139-sec-0098">Potential biases in the review process</h3> <p>Bias in the review process was minimised by the use of comprehensive search terms across six separate medical bibliographic databases including the Cochrane Central Register of Controlled Trials. In addition, the manufacturers' registers of trials were manually searched and respiratory journals were handsearched for additional references. All references were cross‐checked against clincicaltrials.gov, and an additional search of this database was performed. Two review authors independently determined inclusion and exclusion of trials, extracted data and judged risk of bias to minimise error. </p> <p>For continuous outcomes, in most cases mean adjusted data were extracted from published ANCOVA analyses. However in some instances only raw end‐of‐study data were available, and when this was the case, we combined adjusted and raw data (<a href="#CD010139-tbl-0003">Table 1</a> and <a href="#CD010139-tbl-0004">Table 2</a>). It is possible that this approach may have introduced some bias into the results, although the overall effect of this is likely to be very low. One open‐label study comparing indacaterol versus alternative long‐acting beta<sub>2</sub>‐agonists reported quality of life data that could not be used in this review; this may have introduced bias (<a href="./references#CD010139-bbs2-0005" title="IzbickiG , ShitritD , RazM , Vilayi‐WeilerZ , FinkG , SchwarzY , et al. Real‐life efficacy of indacaterol and other LABAs in COPD patients in Israel. Chest2014;145(3):431B. [DOI: 10.1378/chest.1829807] ">Izbicki 2014</a>). However only 90 participants were included in this study and the overall impact is likely to be very low. </p> <p>Most reported data were obtained from methodologically robust randomised controlled trials, and the potential for introduction of significant systematic biases within these trials generally is believed to be low. Rates of attrition were generally between 10% and 20%, often with slightly greater loss of participants from placebo than from experimental arms. Loss to follow‐up was most commonly due to unsatisfactory therapeutic effect or to adverse events. It is possible therefore that unmatched attrition between placebo and experimental arms may have introduced some bias, and such bias would most likely lead to underestimation of the treatment effects of indacaterol. However, again the overall impact of such bias is likely to be low. </p> </section> <section id="CD010139-sec-0099"> <h3 class="title" id="CD010139-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD010139-bbs2-0034" title="HanJ , DaiL , ZhongN . Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta‐analysis of randomised placebo‐controlled trials. BMC Pulmonary Medicine2013;13:26. [DOI: 10.1186/1471‐2466‐13‐26] ">Han 2013</a> performed a systematic review comparing the odds of a clinically significant improvement in dyspnoea with indacaterol versus placebo, and their results are consistent with the findings of this review. As in this review, investigators demonstrated increased odds of achieving a TDI improvement greater than or equal to one point with 75 mcg, 150 mcg and 300 mcg doses of indacaterol compared with placebo, with similar estimates of effect noted across all doses. </p> <p><a href="./references#CD010139-bbs2-0041" title="RodrigoG , NeffenH . Comparison of indacaterol with tiotropium or twice‐daily long‐acting beta agonists for stable COPD. Chest2012;145(5):1104‐10. ">Rodrigo 2012</a> performed a systematic review that included a comparison of any dose of indacaterol versus tiotropium and alternative long‐acting beta<sub>2</sub>‐agonists, and assessed trough FEV<sub>1</sub> and the odds of clinically significant improvements in dyspnoea and quality of life. This study demonstrated a similar small improvement in trough FEV<sub>1</sub> with indacaterol at any dose compared with twice‐daily beta<sub>2</sub>‐agonists. However, in contrast to this review, the odds of achieving a clinically significant improvement in quality of life were greater with indacaterol than with alternative long‐acting beta<sub>2</sub>‐agonists. This finding was due to a greater estimate of effect in pooled results from <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a>. The reason for this difference is unclear, although fewer participants were analysed in our 52‐week analysis for this outcome than were reported in <a href="./references#CD010139-bbs2-0041" title="RodrigoG , NeffenH . Comparison of indacaterol with tiotropium or twice‐daily long‐acting beta agonists for stable COPD. Chest2012;145(5):1104‐10. ">Rodrigo 2012</a>. Data were insufficient for this outcome, and unadjusted 52‐week data were supplied for this review by the manufacturer upon request. Therefore in our review, this outcome will not include imputed data from participants who dropped out of the study. In addition we performed a fixed‐effect generic inverse variance analysis, whereas these review authors performed a Mantel‐Haenszel meta‐analysis using a random‐effects model to account for differences in participant demographics and trial methodologies. <a href="./references#CD010139-bbs2-0041" title="RodrigoG , NeffenH . Comparison of indacaterol with tiotropium or twice‐daily long‐acting beta agonists for stable COPD. Chest2012;145(5):1104‐10. ">Rodrigo 2012</a> also demonstrated increased odds of a clinically significant improvement in dyspnoea for indacaterol compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists, whereas we found no significant differences between the two interventions. The point estimate of effect for <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> was greater than in our review for this outcome. This review used generic inverse variance to include published 26‐week data, whereas these review authors again used a random‐effects Mantel‐Haenszel meta‐analysis. </p> <p><a href="./references#CD010139-bbs2-0030" title="DecramerM , RossiA , LawrenceD , McBryanD . Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respiratory Medicine2012;106:1706‐14. ">Decramer 2012</a> pooled data from <a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a>, <a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> and <a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> and analysed a maintenance treatment‐naive subgroup. Review authors demonstrated clinically significant improvements in trough FEV<sub>1</sub>, dyspnoea and quality of life for indacaterol 150 mcg and 300 mcg compared with placebo. No significant difference in the hazard ratio was noted for time to first exacerbation, although review authors did report a reduction in risk of exacerbation for participants receiving maintenance treatment. No significant increase in serious adverse events was reported. These results are consistent with the findings of this review and suggest that findings can be extended to patients not previously given alternative maintenance therapy. </p> <p><a href="./references#CD010139-bbs2-0029" title="ChungVCH , MaPHX , HuiDSC , TamWWS , TangJL . Indacaterol for chronic obstructive pulmonary disease: systematic review and meta‐analysis. PLOS ONEAugust 2013;8(8):1‐12. ">Chung 2013</a> performed a systematic review comparing indacaterol versus placebo and alternative twice‐daily beta<sub>2</sub>‐agonists. This review judged the evidence to be generally of lower quality caused by potential bias associated with unclear sequence generation. The authors of this review believed that risk of bias due to inadequate sequence generation was low across most studies. Compared with placebo, these review authors found a similar clinically relevant improvement in trough FEV<sub>1</sub>. They did not pool results for quality of life or dyspnoea. Compared with twice‐daily long‐acting beta<sub>2</sub>‐agonists, review authors found a similar small improvement in trough FEV<sub>1</sub>. They did not pool results for quality of life or dyspnoea but noted that no significant difference was reported for these outcomes in any of the included trials. </p> <p><a href="./references#CD010139-bbs2-0036" title="JiangFM , LiangZA , ZhengQL , WangRC , LiCT . Safety and efficacy of 12‐week or longer indacaterol treatment in moderate‐to‐severe COPD patients: a systematic review. Lung2013;191:135‐46. ">Jiang 2013</a> also performed a systematic review comparing indacaterol versus placebo and alternative bronchodilators (including tiotropium). Compared with placebo, review authors demonstrated similar clinically significant improvements in trough FEV<sub>1</sub> and mean dyspnoea scores. They included fewer trials and tiotropium analyses in their alternative bronchodilator comparisons; therefore these results cannot be directly compared with our own. </p> <p>Finally, model‐based approaches have suggested a dose‐response relationship below 150 mcg (<a href="./references#CD010139-bbs2-0038" title="RenardD , LoobyM , KramerB , LawrenceD , MorrisD , StanskiD . Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model‐based approaches. Respiratory Research2011;12(1):54. [DOI: 10.1186/1465‐9921‐12‐54] ">Renard 2011</a>) and individual trials have suggested that 300 mcg of indacaterol conveyed incremental benefits above 150 mcg with respect to symptom control, as evidenced by lower dyspnoea scores and less requirement for rescue short‐acting bronchodilator use (<a href="./references#CD010139-bbs2-0040" title="RibeiroM , ChapmanK . Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. International Journal of COPD2012;7:145‐52. ">Ribeiro 2012</a>). No clear dose‐response effect was seen across the range of outcomes and analyses included in our review, although the incremental response with 300 mcg versus 150 mcg indacaterol has been reported in participants with more severe COPD (<a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a>), and we were unable to perform subgroup analysis by severity of COPD. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010139-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010139-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010139-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Cates plot. Participants with a clinically significant improvement in quality of life with indacaterol compared with placebo." data-id="CD010139-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Cates plot. Participants with a clinically significant improvement in quality of life with indacaterol compared with placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Cates plot. Participants with a clinically significant improvement in dyspnoea with indacaterol compared with placebo." data-id="CD010139-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Cates plot. Participants with a clinically significant improvement in dyspnoea with indacaterol compared with placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 1 Trough FEV1 (by dose)." data-id="CD010139-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 1 Trough FEV<sub>1</sub> (by dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 2 Trough FEV1 (by trial duration)." data-id="CD010139-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 2 Trough FEV<sub>1</sub> (by trial duration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 3 Quality of life (by dose)." data-id="CD010139-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 3 Quality of life (by dose).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 4 Quality of lIfe (by trial duration)." data-id="CD010139-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 4 Quality of lIfe (by trial duration).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 5 Number of participants with a clinically significant improvement in quality of life (by dose)." data-id="CD010139-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 5 Number of participants with a clinically significant improvement in quality of life (by dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 6 Number of participants with a clinically significant improvement in quality of life (by trial duration)." data-id="CD010139-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 6 Number of participants with a clinically significant improvement in quality of life (by trial duration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 7 End‐of‐study dyspnoea (by dose)." data-id="CD010139-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 7 End‐of‐study dyspnoea (by dose).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 8 Number of participants experiencing a clinically significant improvement in dyspnoea." data-id="CD010139-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 8 Number of participants experiencing a clinically significant improvement in dyspnoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 9 Peak FEV1." data-id="CD010139-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 9 Peak FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 10 Serious adverse events." data-id="CD010139-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 10 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 11 Mortality." data-id="CD010139-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 11 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Indacaterol vs placebo, Outcome 12 Number of participants experiencing at least 1 protocol‐defined exacerbation." data-id="CD010139-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Indacaterol vs placebo, Outcome 12 Number of participants experiencing at least 1 protocol‐defined exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 1 Trough FEV1 (by dose)." data-id="CD010139-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 1 Trough FEV<sub>1</sub> (by dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 2 Trough FEV1 (by trial duration)." data-id="CD010139-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 2 Trough FEV<sub>1</sub> (by trial duration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 3 Quality of life (by dose)." data-id="CD010139-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 3 Quality of life (by dose).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 4 Quality of lIfe (by trial duration)." data-id="CD010139-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 4 Quality of lIfe (by trial duration).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 5 Number of participants with a clinically significant improvement in quality of life (by dose)." data-id="CD010139-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 5 Number of participants with a clinically significant improvement in quality of life (by dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 6 Number of participants with a clinically significant improvement in quality of life (by trial duration)." data-id="CD010139-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 6 Number of participants with a clinically significant improvement in quality of life (by trial duration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 7 Dyspnoea (by dose)." data-id="CD010139-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 7 Dyspnoea (by dose).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 8 Number of participants experiencing a clinically significant improvement in dyspnoea." data-id="CD010139-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 8 Number of participants experiencing a clinically significant improvement in dyspnoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 9 Peak FEV1 [mL]." data-id="CD010139-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 9 Peak FEV<sub>1</sub> [mL]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 10 Serious adverse events." data-id="CD010139-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 10 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 11 Mortality." data-id="CD010139-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 11 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010139-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/urn:x-wiley:14651858:media:CD010139:CD010139-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_t/tCD010139-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Indacaterol vs LABAs, Outcome 12 Number of participants experiencing at least 1 protocol‐defined exacerbation." data-id="CD010139-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Indacaterol vs LABAs, Outcome 12 Number of participants experiencing at least 1 protocol‐defined exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/media/CDSR/CD010139/image_n/nCD010139-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010139-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Indacaterol versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Indacaterol versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> indacaterol </p> <p><b>Comparator:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Indacaterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐study trough FEV<sub>1</sub> </b> <br/> mL<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in control groups was<br/> <b>1170 to 1360 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in the intervention groups was<br/> <b>149.11 mL higher</b> <br/> (137.09 to 161.12 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5001<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This value is greater than the minimum clinically important difference of 100 mL (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with a clinically significant improvement in QOL</b> <br/> SGRQ<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>548 per 1000</b> <br/> (519 to 578)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.64</b> <br/> (1.46 to 1.845 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4906<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with clinically significant improvement in dyspnoea</b> <br/> TDI<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> <br/> (576 to 636)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.96</b> <br/> (1.73 to 2.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4577<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing 1 or more exacerbations</b> <br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> <br/> (167 to 212) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b> <br/> (0.7 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4807<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (60 to 87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b> <br/> (0.82 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6065<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (1 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.42</b> <br/> (0.16 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5694<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk calculated from raw responder numbers in placebo arm at end of treatment. Absolute benefit and 95% CIs calculated from <a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>.<br/> <sup>b</sup>95% CIs around the point estimate of effect include both appreciable benefit and no difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Indacaterol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010139-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Indacaterol versus twice‐daily long‐acting beta2‐agonists for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Indacaterol versus twice‐daily long‐acting beta<sub>2</sub>‐agonists for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> indacaterol<br/> <b>Comparison:</b> twice‐daily long‐acting beta<sub>2</sub>‐agonists </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Twice‐daily long‐acting beta<sub>2</sub>‐agonists</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Indacaterol </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐of‐study trough FEV<sub>1</sub> </b> <br/> mL<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in the control groups was <b>1310 to 1390 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean end‐of‐study trough FEV<sub>1</sub> in the intervention groups was<br/> <b>73.76 mL higher</b> <br/> (57.33 to 90.19 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2708<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This value is less than the minimum clinically important difference of 100 mL<sup>d</sup> (<a href="./references#CD010139-bbs2-0031" title="DonahueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111‐24. ">Donahue 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with a clinically significant improvement in quality of life</b> <br/> SGRQ<br/> Follow‐up: 26 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>498 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>515 per 1000</b> <br/> (464 to 567)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.07</b> <br/> (0.87 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1520<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with a clinically significant improvement in dyspnoea</b> <br/> TDI<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b> <br/> (566 to 647)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b> <br/> (0.94 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2536<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing at least 1 exacerbation</b> <br/> Exacerbations<br/> Follow‐up: 26 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> <br/> (215 to 297) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.07</b> <br/> (0.86 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1869<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Adverse events<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> <br/> (63 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.02</b> <br/> (0.79 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3266<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Deaths<br/> Follow‐up: 12 to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (1 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b> <br/> (0.31 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3266<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk taken from raw responder numbers at the end of treatment. Absolute risk and 95% CIs calculated from <a href="http://www.nntonline.net/visualrx" target="_blank">www.nntonline.net/visualrx</a>.<br/> <sup>b</sup>95% CIs around the point estimate of effect include both no difference and appreciable benefit.<br/> <sup>c</sup>95% CIs around the point estimate of effect include both significant benefit and significant harm. </p> <p><sup>d</sup>Minimum clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Indacaterol versus twice‐daily long‐acting beta2‐agonists for chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010139-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data extraction for indacaterol versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> FEV<sub>1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean SGRQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> SGRQ responders</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI responders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0004" title="FeldmanG , SilerT , PrasadN , JackD , PiggottS , OwenR , et al. Efficacy and safety of indacaterol 150mcg once‐daily in COPD: a double‐blind randomised 12‐week study. BMC Pulmonary Medicine2010;10:11. ">Feldman 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0003" title="DonahueJF , FogartyC , LotvallJ , MahlerD , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. ">Donohue 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0008" title="KinoshitaM , LeeSH , HangLW , IchinoseM , HosoeM , OkinoN , et al. Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12‐week placebo controlled study. Respirology2012;17:379‐89. ToY , KinoshitaM , LeeSH , HangLW , IchinoseM , FukuchiY , et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12‐week study in an Asian population. Respiratory Medicine2012;106:1715‐21. ">Kinoshita 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0011" title="MrozR.M , MinarowskiL , ChyczewskaE . Indacaterol add‐on therapy improves lung function, exercise capacity and life quality of COPD patients. Advances in Experimental Medicine and Biology2013;756:23‐8. [DOI: 10.1007/978‐94‐007‐4549‐0_4; ISSN: 0065‐2598] ">Mroz 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0001" title="BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal 2013 May 30 [Epub ahead of print]. [DOI: 10.1183/09031936.00200212] ">Bateman 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0013" title="YaoW , WangC , ZhongN , HanX , ChangguiW , YanX , et al. Effect of once‐daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26‐week Asia‐Pacific study. Respirology2014; Vol. 19:231‐8. [DOI: 10.1111/resp.12211; CQAB149B2333] ">Yao 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0006" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 1</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0007" title="GotfriedM , KerwinE , LawrenceD , LassenC , KramerB . Efficacy of Indacaterol 75mcg once‐daily on dyspnea and health status: results of two double‐blind, placebo‐controlled 12‐week studies. COPD2012;9(6):629‐36. KerwinE , GotfriedM , LawrenceD , LassenC , KramerB . Efficacy and tolerability of indacaterol 75mcg once daily in patients aged &gt; 40 years with chronic obstructive pulmonary disease: results from 2 double‐blind, placebo‐controlled 12 week studies. Clinical Therapeutics2011;33(12):1974‐84. ">Kerwin 2011 Study 2</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Raw data used for analysis by trial duration (12‐week data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data extraction for indacaterol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010139-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data extraction for indacaterol versus alternative twice‐daily long‐acting beta2‐agonists</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> FEV<sub>1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean SGRQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> SGRQ responders</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean TDI responders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0002" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65:473‐9. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life (HRQOL) in COPD: a 52‐week study. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009. ">Dahl 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0009" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12‐week study. Respiratory Medicine2011;105:719‐26. ">Korn 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0010" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37:273‐9. ">Kornmann 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010139-bbs2-0012" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study. Respirology2011;16(2):96. ">To 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not analysed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>12‐Week raw data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data extraction for indacaterol versus alternative twice‐daily long‐acting beta2‐agonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/full#CD010139-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010139-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Indacaterol vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Trough FEV<sub>1</sub> (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>149.11 [137.09, 161.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>130.0 [101.72, 158.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>146.52 [129.94, 163.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>169.27 [144.52, 194.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>150.0 [100.62, 199.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Trough FEV<sub>1</sub> (by trial duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>149.16 [137.06, 161.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials &lt; 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>148.99 [129.11, 168.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials ≥ 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>149.26 [134.01, 164.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐4.36, ‐2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐5.66, ‐1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.43 [‐4.53, ‐2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.49 [‐4.94, ‐2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.6 [‐7.07, ‐2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of lIfe (by trial duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.44 [‐4.25, ‐2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials &lt; 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.11 [‐5.60, ‐2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials ≥ 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.15 [‐4.12, ‐2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants with a clinically significant improvement in quality of life (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.46, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.24, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.41, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Indcaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.15, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.30, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants with a clinically significant improvement in quality of life (by trial duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.38, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials &lt; 24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.51, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials ≥ 24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.26, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 End‐of‐study dyspnoea (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.83, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.27, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.51, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants experiencing a clinically significant improvement in dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.73, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.26, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.56, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.81, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.20, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Peak FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>181.21 [129.10, 233.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>196.56 [107.15, 285.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>200.91 [111.71, 290.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>173.50 [69.92, 277.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Indacterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.0 [‐172.77, 232.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.24, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.74, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.65, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.16, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Indacaterol 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.23, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.02, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.00, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number of participants experiencing at least 1 protocol‐defined exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 75 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.49, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.65, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Indacaterol vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010139-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Indacaterol vs LABAs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Trough FEV<sub>1</sub> (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>73.76 [57.33, 90.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>62.56 [42.71, 82.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Indcaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>97.17 [60.51, 133.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>100.0 [51.21, 148.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Trough FEV<sub>1</sub> (by trial duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>94.93 [79.58, 110.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials &lt; 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>60.0 [37.00, 83.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials ≥ 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>122.98 [102.37, 143.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐2.28, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.2 [‐3.42, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐3.27, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐3.27, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of lIfe (by trial duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [‐1.21, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials ≥ 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [‐1.21, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants with a clinically significant improvement in quality of life (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.87, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.85, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.63, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.74, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants with a clinically significant improvement in quality of life (by trial duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.86, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials ≥ 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.86, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Dyspnoea (by dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.30, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Indcaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.37, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.46, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.3 [‐0.35, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants experiencing a clinically significant improvement in dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.94, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.98, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.59, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.72, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Peak FEV<sub>1</sub> [mL] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [‐93.79, 103.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.0 [‐113.72, 193.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.0 [‐212.29, 152.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.0 [‐190.45, 170.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.92, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.66, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.31, 3.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [0.35, 15.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.11, 6.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number of participants experiencing at least 1 protocol‐defined exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 indacaterol 150 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.80, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 indacaterol 300 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.74, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 indacaterol 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.62, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Indacaterol vs LABAs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010139.pub2/references#CD010139-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010139.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010139-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010139-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010139-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010139-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010139-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010139-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010139-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010139\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010139\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010139\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010139\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010139\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010139.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010139.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010139.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010139.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010139.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714313630"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010139.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714313634"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010139.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6ba20d90f3cd',t:'MTc0MDcxNDMxMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 